[1,1'-biphenyl]-4-yl(3-(2-((4,5-dichloro-1H-imidazol-1-yl)methyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone | 1338373-98-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [1,1'-biphenyl]-4-yl(3-(2-((4,5-dichloro-1H-imidazol-1-yl)methyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone
• 英文别名: [1,1''-biphenyl]-4-yl(3-(2-((4,5-dichloro-1H-imidazol-1-yl)methyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone；[3-[2-[(4,5-dichloroimidazol-1-yl)methyl]-1,3-thiazol-4-yl]-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-phenylphenyl)methanone
• CAS: 1338373-98-0
• 化学式: C₂₅H₁₉Cl₂N₇OS
• 分子量: 536.444
• InChiKey: CCVCVKDIALEGBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  110
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS
  申请人：Euroscreen S.A.

  公开号：US20140371218A1

  公开（公告）日：2014-12-18

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及一种新型化合物I的配方及其作为治疗化合物的用途。
• NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
  申请人：Ogeda SA

  公开号：US10065960B2

  公开（公告）日：2018-09-04

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及式 I 的新型化合物 及其作为治疗化合物的用途。
• US8871761B2
  申请人：——

  公开号：US8871761B2

  公开（公告）日：2014-10-28